Prevalence and determinants of metabolic syndrome and pre-frailty comorbidity in elderly: results from the WhiteHall II study

### Steve NJOUONKEP (PhD Student)

Platform of Metabolic Exploration, MetaboHUB Clermont, MAPPING group Unit of Human Nutrition, INRAE, Clermont Auvergne University,

France



INRA



Between 2000 and 2050, the **proportion of the world's population over 60 y.o. will double** from about 11% to 22%; 30% in Europe.

In Europe, in 2022, **life expectancy**: 80.3 years (up by 0.5 years from 2021).


- 83.3 yrs for women (0.4 higher than in 2021)
- 77.9 yrs for men (0.7 higher than in 2021)


Healthy life expectancy (without incapacities in quotidian life):

- 64.2 yrs for women (77.4 % of life expectancy)
- 63.1 yrs for men (81.7 % of life expectancy)











## AGEING



## **GERIATRIC SYNDROMES**



24 - 27 SEPTEMBER 2024


Very high prevalence (25% world population, up to 40% > 65 y.o.)

INRAC

➢ Prevalence from 12% to up to 20%

Viscogliosi, 2016 McCarthy, 2023 Barzilay, 2007 Crow, 2019 Bastos-Barbosa, 2012

## **STUDY OBJECTIVE**





**PREVALENCE & DETERMINANTS OF METS - PRE-FRAILTY COMORBIDITY IN ELDERLY** 


## METHODOLOGY

WhiteHall II: Stress and Health Study to investigate the causes of social inequalities in health and for studies on ageing




- Frailty (n=116)

3,398 subjects





- Multinomial logistic regression: adjusted for
- sociodemographic, lifestyle & health data
- Interaction: Age & sex





N: 3,398 Age: 71.9 (5.5) y.o. Male: 73.6 % **Characteristics of Comorbid subjects** Older, Male, Non-Caucasian, Overweight, Former smokers, Single/widowed, Highly sedentary, Low physical activity levels, Consumed Less than 1 fruit/veg per day, Diabetic Low physical SF36 Low mental SF36





#### **STUDY OF SUB-PHENOTYPES OF AGEING SYNDROMES**

**MetS sub-phenotypes** 

## TAKE HOME MESSAGE

- Notable prevalence of MetS pre-frailty comorbidity among elderly, underscoring the widespread coexistence of these conditions in this population.
- Several determinants were associated with an increased likelihood of MetS pre-frailty comorbidity. These findings highlight the need for targeted interventions to address these risk factors.
- While MetS, pre-frailty, and their comorbidity share several determinants, the study reveals that their effects on each condition may significantly differ.

This suggests that the MetS - pre-frailty comorbidity should be regarded as a distinct pathological state requiring specific clinical attention.





#### **ACKNOWLEDGEMENTS**





METABOLIC PHENOTYPE, NUTRITION AND MODELING





Blandine COMTE Estelle PUJOS-GUILLOT Léopold FEZEU PhD directors and supervisor





CRESS

*weren* 

I-SITE

**Clermont Auvergne Project** 



All participants in the Whitehall II Study, Whitehall II researchers and support staff.

RESS

EpiAgeing

#### **University College of London**



Whitehall II study





Archana Singh-Manoux

Benjamin Landre



# Thank you very much for your attention







